Recent advances in immunotherapy have not addressed the challenge presented by ovarian cancer. Although the peritoneum is an “accessible” locus for this disease there has been limited characterization of the immunobiology therein. We investigated the ID8-C57BL/6J ovarian cancer model and found marked depletion of B1 cells from the ascites of the peritoneal cavity. There was also selective loss of the B1 and marginal zone B cell subsets from the spleen. Immunity to antigens that activate these subsets validated their loss rather than relocation. A marked influx of myeloid-derived suppressor cells correlated with B cell subset depletion. These observations are discussed in the context of the housekeeping burden placed on innate B cells during ovarian cancer and to foster consideration of B cell biology in therapeutic strategies to address this challenge.

免疫疗法的最新进展尚未解决卵巢癌带来的挑战。尽管腹膜是这种疾病的“可接近”部位，但其中的免疫生物学特征仍然有限。我们研究了 ID8-C57BL/6J 卵巢癌模型，发现腹膜腔腹水中的 B1 细胞明显减少。脾脏中的B1 细胞和边缘区 B 细胞亚群也选择性丢失。对激活这些亚群的抗原的免疫证实了它们的丢失而不是重新定位。骨髓源性抑制细胞的显着流入与 B 细胞亚群耗竭相关。这些观察结果是在卵巢癌期间对先天 B 细胞造成的管家负担的背景下讨论的，并促进在应对这一挑战的治疗策略中考虑 B 细胞生物学。